Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 28, 2025
Daily News
April 28, 2025
- Moderna Taps Asia Chief as Japan Representative Director, Marketing Head as GM
April 28, 2025
- Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
April 28, 2025
- Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
- Daiichi Sankyo Marks 2-Digit Growth in Sales, Net Profit Driven by Enhertu
April 28, 2025
- Rohto Kicks Off Japan PII for Regenerative Medicine for Heart Failure
April 28, 2025
- Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
- Sanofi’s Dupixent Filed for Bullous Pemphigoid in Japan
April 28, 2025
- ASKA’s Contraceptive, Vabysmo Label Expansion Now in Line for Japan Approval
April 28, 2025
- Seikagaku, Ono to Tie Up on Osteoarthritis Drug in Japan
April 28, 2025
- MHLW/PMDA, FDA Philippines to Boost Regulatory Cooperation
April 28, 2025
- The Evolution of HR: From BP to Agile
April 28, 2025
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…